文献速递骨肌神经介入CTDSA

脊柱动脉瘤样骨囊肿导致神经功能受损:十四烷基硫酸钠泡沫硬化治疗的安全性与临床疗效

Aneurysmal bone cysts in the spine, causing neurological compromise: safety and clinical efficacy of sclerotherapy utilizing sodium Tetradecyl sulfate foam.
PubMed 文献 · Skeletal Radiol · 2021-05-20

本研究评估经皮硬化治疗使用十四烷基硫酸钠泡沫(STS)作为一线方案,治疗导致神经功能受损的侵袭性脊柱动脉瘤样骨囊肿(sABCs)的临床疗效、技术可行性和安全性。2013年7月至2019年9月,8例连续患者(5男3女,平均年龄22±17岁,范围7-52岁)接受透视/CT引导下骨内硬化治疗。2例因脊髓压迫持续神经功能缺损需手术切除(排除在最终结局分析外)。其余6例在长达5年随访(平均20±16.7个月,范围7-51个月)中,肿瘤体积(p=0.028)、疼痛(p=0.027)和脊柱不稳肿瘤评分(SINS)(p=0.027)均显著降低。结论认为STS经皮硬化治疗是微创、技术可行、安全有效的一线治疗,可避免广泛手术,对接受3个或以上治疗周期、初始SINS较高、疼痛评分较高或肿瘤体积较大的患者最为有效。

要点

  • 经皮STS泡沫硬化治疗脊柱动脉瘤样骨囊肿技术成功率高,可有效缩小肿瘤体积、减轻疼痛并降低SINS评分。
  • 2/8例(25%)因脊髓压迫导致持续性神经功能缺损需手术切除,虽硬化治疗成功但神经功能未恢复。
  • 治疗周期≥3个、初始SINS较高、疼痛评分较高或肿瘤体积较大的患者疗效更佳。

核心结论

  • 经皮STS泡沫硬化治疗是微创、技术可行、安全且有效的一线治疗,适用于引起疼痛和神经功能受损的原发性脊柱动脉瘤样骨囊肿,可避免广泛手术;对接受3个或以上治疗周期、初始SINS较高、疼痛评分较高或肿瘤体积较大的患者最为有效。

研究设计与样本

  • 单中心连续病例系列,2013年7月至2019年9月纳入8例(5男3女,平均年龄22±17岁,范围7-52岁)导致神经功能受损的脊柱动脉瘤样骨囊肿患者,接受透视/CT引导下骨内注射十四烷基硫酸钠泡沫(STS)硬化治疗;分析手术数据、并发症、影像学和临床结果;2例因持续神经功能缺损需手术切除而被排除在最终结局分析外,最终分析6例。

诊断标准与关键数值

  • 每次手术平均使用2.6ml±1.3(范围1-6)的3% STS泡沫,平均治疗周期3.7±1.2次(范围1-5次),平均手术时间25±15分钟(范围6-167分钟),每次手术平均剂量长度乘积(DLP)为158±91 mGy*cm(范围62-331)。
  • 最终分析的6例患者随访至5年(平均20±16.7个月,范围7-51个月),肿瘤体积显著缩小(p=0.028)、疼痛显著减轻(p=0.027)、SINS显著降低(p=0.027)。
  • 2例(25%)虽硬化治疗成功,但因脊髓压迫导致持续性神经功能缺损,需行手术切除。

临床应用与阅片要点

  • 对于导致疼痛和/或神经功能受损的脊柱动脉瘤样骨囊肿,可考虑将经皮STS泡沫硬化治疗作为一线微创治疗选择。
  • 治疗周期≥3个、初始SINS较高、疼痛评分较高或肿瘤体积较大的患者可能从硬化治疗中获益更明显。
  • 需警惕部分患者虽硬化治疗成功,但仍可能因脊髓压迫而持续存在神经功能缺损,最终需手术切除。

局限性

  • 2例患者因持续神经功能缺损需手术切除而被排除在最终结局分析之外。
  • 本研究为单中心小样本连续病例系列(8例),最终分析仅6例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the clinical efficacy, technical feasibility, and safety profile of percutaneous sclerotherapy utilizing sodium tetradecyl-sulfate foam (STS) as a first-line treatment strategy for aggressive spinal aneurysmal bone cysts (sABCs) presenting with neurological compromise.

MATERIALS AND METHODS: Between July 2013 and September 2019, eight consecutive patients (5 males; 3 females; mean age 22±17, range 7-52) underwent fluoroscopic/CT-guided intraosseous sclerotherapy for sABCs. Pain and/or neurological compromise was the primary indications. Procedural data, complications, imaging, and clinical results were analyzed.

RESULTS: Technical success was achieved in all cases. Mean procedure time was 25±15 min (range 6-167); 1 to 5 repeat treatment cycles (mean 3.7±1.2) utilizing a mean 2.6mls±1.3 (range 1-6) of agitated 3% STS, with a DLP mean dose of 158±91 mGy*cm (range 62-331) per procedure. One reported a minor complication (pain), but no significant complications. Two patients had persistent neurological deficit due to cord compression despite successful sclerotherapy, requiring surgical resection (and were thereby excluded from the final outcome analysis). The remaining six patients demonstrated a significant reduction in tumor volume (p = 0.028), pain (p = 0.027), and SINS (spinal instability neoplastic score) (p = 0.027) at up to 5 years of follow-up (mean 20 ± 16.7, range 7-51 months).

CONCLUSION: Percutaneous sclerotherapy with STS is a minimally invasive, technically feasible, safe, and effective first-line treatment for primary sABCs causing pain and neurological compromise, alleviating the need for extensive surgery. It is most effective with three or more treatment cycles, in patients with higher SINS, pain scores, or tumor volumes at the initial presentation.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Dalili D, Parker J, Mirzaian A, et al. Aneurysmal bone cysts in the spine, causing neurological compromise: safety and clinical efficacy of sclerotherapy utilizing sodium Tetradecyl sulfate foam. Skeletal Radiol. 2021. PMID: 34013448. doi:10.1007/s00256-021-03793-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。